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A B S T R A C T
An 89-year-old man visited our hospital complaining of palpitation. Electrocardiography showed atrial
ﬁbrillation, and transthoracic echocardiography demonstrated a mobile thrombus of
28.6 mm  20.8 mm in the left atrium. Administration of a direct factor Xa inhibitor rivaroxaban
(10 mg/day) was started. The thrombus reduced its size and disappeared completely 2 weeks after the
commencement of rivaroxaban treatment. To our knowledge, this is the ﬁrst case report that
rivaroxaban successfully dissolved left atrial thrombus during a short period. Rivaroxaban might have a
potential, not only to prevent de novo thrombus formation, but also to dissolve established thrombi by
direct inhibition of free and thrombus-associated factor Xa.
<Learning objective: The incidence of nonvalvular atrial ﬁbrillation is increasing, and left atrial
thrombus is the major cause of cardiogenic thrombo-embolism that we need to prevent. Recently, novel
oral anticoagulants have been developed. The effects of these agents on intracardiac thrombus resolution
have not been fully elucidated. Data from a large cohort study would be required to assess efﬁcacy of
novel oral anticoagulants for thrombus resolution.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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The incidence of nonvalvular atrial ﬁbrillation increases with
age, and left atrial thrombus complicated with nonvalvular atrial
ﬁbrillation is the major direct cause of cardiogenic thrombo-
embolism that we need to prevent. Intravenous heparin and oral
vitamin-K antagonist warfarin have been the most popular and the
most frequently used agents for the treatment of left atrial
thrombus in patients with atrial ﬁbrillation [1]. Recently, novel oral
anticoagulants such as a direct thrombin inhibitor dabigatran or a
direct factor Xa inhibitor rivaroxaban have been developed, and we
can use these agents in the clinical settings to prevent cardiogenic
thrombo-embolism in patients with nonvalvular atrial ﬁbrillation
[2]. We experienced an atrial ﬁbrillation patient with intracardiac* Corresponding author at: Department of Clinical Research, National Hospital
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1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightlarge thrombus, which shrunk and then disappeared during a short
period after starting treatment with rivaroxaban.
Case report
An 89-year-old man visited our hospital complaining of
palpitation. Blood pressure was 156/88 mmHg and electrocardi-
ography showed atrial ﬁbrillation with a ventricular rate of
88. Blood tests revealed hemoglobin A1c 7.9%, brain natriuretic
peptide 175.6 pg/ml, D-dimer 1.7 mg/ml, prothrombin time-
international normalized ratio 1.08, activated partial thrombo-
plastin time 27.9%, and creatinine clearance 47.5 ml/min. The
CHADS2 score was assessed as 3. Transthoracic echocardiography
demonstrated a mobile thrombus of 28.6 mm  20.8 mm in the
left atrium (Fig. 1). We administered 4000 units of heparin
intravenously and simultaneously prescribed rivaroxaban
10 mg/day. After 5 days of rivaroxaban treatment, transthoracic
echocardiography showed that the thrombus shrunk to
20.3 mm  15.6 mm (Fig. 2). After 14 days of treatment, the
thrombus disappeared completely not only on transthoracic
echocardiography but also on transesophageal echocardiographys reserved.
Fig. 1.
Transthoracic echocardiography at visit demonstrated a mobile
thrombus of 28.6 mm  20.8 mm (arrows) in the left atrium. LA, left
atrium; LV, left ventricle.
Fig. 2.
After 5 days of rivaroxaban 10 mg/day treatment, transthoracic
echocardiography showed that the thrombus shrunk to
20.3 mm  15.6 mm (arrows). LA, left atrium; LV, left ventricle.
Fig. 3.
After 14 days of treatment with rivaroxaban 10 mg/day, the thrombus
disappeared completely on transesophageal echocardiography.
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any bleeding complication (Fig. 3).
Discussion
The effects of novel oral anticoagulants on intracardiac
thrombus resolution in patients with nonvalvular atrial ﬁbrillation
have not been fully elucidated. Morita et al. [3] reported a case of
thrombus of 26.0 mm  30.0 mm in the left atrium, which
disappeared after 4 months of dabigatran therapy (300 mg/day).
Vidal and Vanerio [4] reported a case, in whom 6 weeks of
dabigatran therapy (300 mg/day) shrunk and resolved left atrial
thrombus. We also previously reported that [5] low-dose
dabigatran was not sufﬁcient to reduce the size of a left atrial
thrombus. In the case, a 6-week treatment with dabigatran
(220 mg/day) increased the thrombus size from 10 mm  22 mm
to 15 mm  30 mm. After changing dabigatran to warfarin with
adequate prothrombin time/international normalization ratio of
2.0–3.0, the thrombus subsequently shrunk and then disappeared
36 days after changing to warfarin. The results suggest that low-
dose dabigatran is ineffective for the thrombus size reduction.On the other hand, in our present case, the left atrial thrombus
of 28.6 mm  20.8 mm had completely disappeared after only
2 weeks of treatment with rivaroxaban 10 mg/day, without any
evidence of systemic thrombo-embolism and any bleeding
complications, even though we did not examine by computed
tomography/magnetic resonance imaging.
Dabigatran and rivaroxaban have peaks and troughs in their
concentration curves. Rivaroxaban exhibits anticoagulation activ-
ity by direct inhibition of factor Xa at its peak level, but may not
inhibit the coagulation cascade at the trough level. The antith-
rombotic effect of rivaroxaban is thought to be present even in the
trough level, because of the presence of physiological coagulation
inhibitors, such as tissue factor pathway inhibitor, antithrombin,
protein C, protein S, and the ﬁbrinolytic system. Therefore, once-
daily intermittent anticoagulation by rivaroxaban effectively
suppresses continuous thrombin activity.
The reduction of the left atrial thrombus size by anticoagulant
therapy may be due to relatively predominant ﬁbrinolytic activity
rather than inhibition of thrombin activity [6]. However, the
predominance of ﬁbrinolytic activity in the trough level by the
low-dose dabigatran is too weak to achieve sufﬁcient thrombus
size reduction, compared with that by rivaroxaban. In a recent
study, Sadeghi et al. [7] focused on the different effects on tissue
factor-mediated thrombin generation between dabigatran and
rivaroxaban. According to their study, rivaroxaban inhibited the
conversion of prothrombin to thrombin, whereas dabigatran did
not. Unlike dabigatran, rivaroxaban exhibited strong inhibition of
thrombin generation even at lower concentration. These results
might explain the different effect on left atrial thrombus reduction
between rivaroxaban and dabigatran in patients with nonvalvular
atrial ﬁbrillation.
From our case, we can envision that rivaroxaban might have a
potential, not only to prevent de novo thrombus formation, but
also to dissolve established thrombi by direct inhibition of free and
thrombus-associated factor Xa. However, we need to heed that our
present report is only based on a single case and data from a large
cohort study would be required to assess efﬁcacy of novel oral
anticoagulants for thrombus reduction.
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